RedHill Biopharma Ltd (RDHL)

[DorseyE]

In parallel, RedHill is rapidly advancing its development program with opaganib in severe COVID-19 pneumonia; The U.S. Phase 2 study is fully enrolled with topline data expected within weeks, and a global Phase 2/3 study which is more than 50% enrolled, with topline data expected in Q1/2021 in support of potential emergency use applications